Nearly 100 more Januvia lawsuit claims, as well as other cases involving similarly-designed diabetes medications, have been added to a federal litigation established in the Southern District of California, according to a recent court update.
A Case List published on January 15th shows that 262 lawsuits involving a class of diabetes drugs known as incretin mimetics are now pending in a federal proceeding that is continuing to grow. A month ago, a document published by the U.S. Judicial Panel on Multidistrict Litigation indicated that the number of cases, many of which including Januvia pancreatic cancer claims, as well as instances of pancreatitis and even thyroid cancer stemming from the diabetes medications, totaled 163. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
It is noteworthy to add that when this diabetes drug proceeding was created in August 2013, only 53 claims had been filed.
The rise in Januvia lawsuit filings may be owed in part to recent scrutiny from the U.S. Food and Drug Administration (FDA), which reportedly began investigating incretin mimetics in March 2013 after the findings of a previously unpublished study showed precancerous cells in the pancreas’ of individuals who took Byetta and other drugs. Although their association with pancreatic cancer is unconfirmed, the FDA’s review on incretin mimetics is ongoing.
A month later, the Institute for Safe Medicine Practices reported 263 instances of pancreatitis, as well as 71 pancreatic cancer cases and 14 incidents of thyroid cancer in individuals taking Byetta, which was the first incretin mimetic to be FDA approved in 2005.
It’s clear that federally-filed lawsuits will make significant headway in the start of the New Year, beginning with two “Science Days,” which were scheduled in November by the federal judge overseeing lawsuits in California. Slated to take place on February 4th and 5th, parties will discuss various medical and scientific issues related to Januvia pancreatic cancer lawsuits, as well as similar actions against incretin mimetics like Byetta and Victoza. Among other items on the agenda, the role of drug therapy in treating diabetes will be discussed; as well information relating to the side effects these diabetes medications may have on the pancreas, as well as other pancreatic cancer information.
The attorneys at Bernstein Liebhard LLP are actively investigating potential claims from diabetics who took Januvia. Call our Firm today to speak with a lawyer: .